Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with cancer that has spread to the brain, confirmed by imaging scans.
- People whose brain tumours (however many there are) are all 2 cm or smaller in size.
- People whose medical team has already planned for them to receive a type of targeted radiation treatment called stereotactic radiosurgery (SRS).
- People who are reasonably active and able to carry out daily activities, as measured by a standard health scale (confirm with trial site).
- People of reproductive potential who are willing to use two highly effective forms of contraception starting at least 4 weeks before screening and continuing until 1 week after the final imaging scan done as part of the trial.
Who may not be able to join:
- People who have previously had a severe allergic reaction (anaphylaxis) to the imaging agent used in this trial, called 18F-fluciclovine.
- People whose scans show cancer has spread along the lining of the brain or spinal cord (a condition called leptomeningeal disease).
- People who have previously had whole-brain radiation therapy.
- People who are unable to have an MRI scan — for example, those who have a pacemaker or another reason that makes MRI unsafe.
- People who are pregnant or who have had a positive pregnancy test within 14 days of joining the trial.
- People who are breastfeeding and are unwilling to pause breastfeeding for 24 hours after the imaging scan.
- People with a serious medical illness or a mental health or cognitive condition that, in the investigator's opinion, would prevent them from completing the trial or from giving informed consent (note: in some cases of cognitive impairment, a legally authorised representative may be able to provide consent on someone's behalf, if the investigator agrees the person could still complete the trial).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rupesh Kotecha, M.D., Miami Cancer Institute at Baptist Health, Inc.
Phone: (786) 596-2000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Standardized Uptake Value (SUV)-peak; Change in SUVmean; Change in SUVmax
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.